Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial - PubMed
6 hours ago
- #daratumumab
- #immune thrombocytopenia
- #phase 2 trial
- All 63 enrolled patients completed the 8-week daratumumab treatment and 16-week follow-up.
- 52 out of 63 patients (83%) achieved the primary endpoint of two or more consecutive platelet counts of at least 50 × 10^9 platelets per L within 8 weeks.
- At week 8, 49 patients (78%) had an overall response, with 32 (51%) achieving a complete response; this response persisted in 38 patients (60%) at week 24.
- Bleeding symptoms (WHO grade 1-4) decreased from 44% of patients at baseline to 10% at week 8.
- Adverse events included infusion-related reactions in 32% of patients (mainly during the first dose) and infections in 32%, primarily upper respiratory tract infections.